Expression of GPR30 obtained from gene expression microarray databases of Vanaja et al.’s [229] and Varambally et al.’s [230] studies and also our cohort of samples [224] showed variations in the expression among clinical samples with slight reduction in PCa as compared to normal tissues, suggesting that the sensitivity to G-1 among patients may be different and expression status of GPR30 could be used as a biomarker for prediction of a patient’s outcomes for GPR30-targeted therapy in future clinical trials. This evidence concerns the gene GPER1 and posterior cortical atrophy.